Healthy Bill

healthybill.net

Healthy Bill is the one stop shop for all your healthcare needs, providing access to inexpensive Diagnostic centers, Pharmacies, Hospitals and Wellness centers. Our mission is to make health care services accessible and affordable to everyone.

Related News

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

news image

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More

CELL AND GENE THERAPY

ZHONGCHAO INC. ANNOUNCES ITS NEW STRATEGY EXTENSION FOCUSING ON THE ONCOLOGY AND OTHER MAJOR DISEASE MANAGEMENT

Zhongchao Inc. | September 02, 2022

news image

Zhongchao Inc. an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated exp...

Read More

INDUSTRIAL IMPACT

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

news image

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More

RESEARCH

SYNTHACE UNVEILS FIRST LIFE SCIENCES R&D CLOUD ADDRESSING COMPLEXITY, SPEED & REPRODUCIBILITY FOR SCIENTISTS

Synthace | August 03, 2021

news image

Synthace, a leading life sciences software company, today announced the first life sciences R&D cloud that includes a no-code software platform addressing the largest barriers to innovation that R&D life scientists currently face. With the release of this new platform, Synthace is also the first vendor to enable scientists to automate experimentation and insight sharing in a unified, global R&D environment. Scientists can now focus on asking the most impactful questions and unlock th...

Read More
news image

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More
news image

CELL AND GENE THERAPY

ZHONGCHAO INC. ANNOUNCES ITS NEW STRATEGY EXTENSION FOCUSING ON THE ONCOLOGY AND OTHER MAJOR DISEASE MANAGEMENT

Zhongchao Inc. | September 02, 2022

Zhongchao Inc. an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated exp...

Read More
news image

INDUSTRIAL IMPACT

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More
news image

RESEARCH

SYNTHACE UNVEILS FIRST LIFE SCIENCES R&D CLOUD ADDRESSING COMPLEXITY, SPEED & REPRODUCIBILITY FOR SCIENTISTS

Synthace | August 03, 2021

Synthace, a leading life sciences software company, today announced the first life sciences R&D cloud that includes a no-code software platform addressing the largest barriers to innovation that R&D life scientists currently face. With the release of this new platform, Synthace is also the first vendor to enable scientists to automate experimentation and insight sharing in a unified, global R&D environment. Scientists can now focus on asking the most impactful questions and unlock th...

Read More